The Kirsten rat sarcoma (KRAS) oncogene is mutated in approximately 95% of all pancreatic cancer cases and acts as the primary regulator of all cellular proliferation pathways in up to 90% of these cases [52,53]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.